Pier Capital’s UroGen Pharma URGN Stock Holding History

Pier Capital’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-150,184	Closed	-$2.68M	–	115
2020 Q1	$2.68M	Buy	+150,184	New	+$4.06M	0.59%	87

Other funds holding URGN

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HCM

Horton Capital Management Philadelphia, Pennsylvania $44.9M AUM 24.87% 1-Year Est. Return

Pier Capital's URGN Position: Q2 2020 in Review

Pier Capital sold out of UroGen Pharma (URGN) in Q2 2020, closing a stake of 150,184 shares — an estimated $2.68M sold.

Pier Capital first reported a position in URGN in Q1 2020 and held it in 1 quarter. The position peaked at $2.68M in Q1 2020. 84 funds tracked by Wall St. Rank hold URGN as of Q2 2020.

Pier Capital reported no remaining UroGen Pharma position as of Q2 2020 after selling out during the quarter.
Pier Capital sold 150,184 UroGen Pharma shares in Q2 2020, an estimated $2.68M.
Pier Capital first reported a position in UroGen Pharma in Q1 2020 and held it in 1 quarter.
Pier Capital's UroGen Pharma position peaked at $2.68M in Q1 2020.
84 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2020.

Based on Pier Capital's 13F filing for Q2 2020, filed 13 Aug 2020.